Compare PCT & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PCT | RCKT |
|---|---|---|
| Founded | 2015 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Environmental Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 340.9M |
| IPO Year | N/A | N/A |
| Metric | PCT | RCKT |
|---|---|---|
| Price | $8.86 | $3.24 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 14 |
| Target Price | $13.67 | ★ $29.12 |
| AVG Volume (30 Days) | ★ 4.0M | 2.0M |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $5,660,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $689.83 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.40 | $2.19 |
| 52 Week High | $17.37 | $13.35 |
| Indicator | PCT | RCKT |
|---|---|---|
| Relative Strength Index (RSI) | 48.04 | 46.08 |
| Support Level | $7.43 | $3.30 |
| Resistance Level | $9.71 | $3.57 |
| Average True Range (ATR) | 0.63 | 0.18 |
| MACD | 0.09 | -0.01 |
| Stochastic Oscillator | 64.58 | 22.81 |
PureCycle Technologies Inc is a Florida-based corporation focused on commercializing a patented dissolution process to physically separate the polymer from other plastics, color, and contaminants (the Technology), originally developed by The Procter & Gamble Company (P&G), for restoring waste polypropylene into resin with near-virgin characteristics, called PureFive resin. PureFive resin represents the family of recycled resin products produced, including ultra-pure resin and other grades used for compounding to meet customer specifications, which has similar properties and applicability for reuse as virgin polypropylene. It has a single operating segment, which encompasses integrated business activities related to the recycling of polypropylene into resins.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.